The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy
- 1Department of Neurosciences, University of Padova, Italy
- 2Children’s Hospital of Pittsburgh, Division of Pediatric Endocrinology, Pittsburgh, PA, USA
- 3Center for Genetic Medicine, Children’s Research Hospital, Washington, DC, USA
- Correspondence to: Dr E Pegoraro Department of Neurosciences, University of Padova, via Giustiniani 5, 35128 Padova, Italy;
- Received 12 August 2005
- Accepted 7 January 2006
- Revised 23 December 2005
Background: Steroid administration is beneficial in Duchenne muscular dystrophy (DMD), but the response, incidence, and the severity of side effects are variable.
Aims: To investigate whether glucocorticoid receptor (GRL) gene polymorphisms may be responsible for glucocorticoid sensitivity in DMD.
Methods: Forty eight DMD patients treated either with prednisone or deflazacort were subjected to genetic analyses of the GRL gene.
Results: Mutation studies revealed an heterozygous A to G mutation at GRL cDNA position 1220 in three DMD patients resulting in an asparagine to serine amino acid change at amino acid position 363 (N363S). The N363S carrier DMD patients showed a trend towards a later age at loss of ambulation in comparison with non-carrier patients.
Conclusions: These data suggest that the N363S GRL polymorphism may be implicated in the long term response to glucocorticoids.
- DMD, Duchenne muscular dystrophy
- PCR, polymerase chain reaction
- SSCP, single strand conformational polymorphism
See Editorial Commentary, p 1104
Competing interests: none.